COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

The game of "enacting power" - the report of the eighth plenary meeting of ISO/TC249 (on)

Page view

Since Zixin Pharmaceutical sponsored the sixth plenary session of TC249 in 2015, it has been actively working for the research and development of international standards for Chinese medicine. Thanks to Hong Kong Baptist University for giving Zixin Pharmaceutical a service for ISO/TC249. Opportunity."

On June 5, 2017, when Guo Chunlin, chairman of Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “Zixin Pharmaceutical”), delivered a speech on the stage of the welcome dinner, his inner joy was beyond his words. He hoped that international friends could Zixin Pharmaceuticals cooperates to make greater contributions to the health of all human beings.

From June 5 to 8, 2017, the eighth plenary meeting of the International Organization for Standardization of Traditional Chinese Medicine Technical Committee (ISO/TC249) was held in Hong Kong with nearly 300 participants. It is worth mentioning that the first Chinese scholar who participated in the formulation of the US Pharmacopoeia Chinese medicine standard, Professor Guo Dean of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was also invited to participate in the meeting.

Zixin Pharmaceutical has become the only authorized support unit of the conference after the sixth plenary meeting of ISO/TC249 held in Beijing in 2015.

As we all know, the standardization of traditional Chinese medicine is "the trend of the trend, the general trend", what kind of contribution has Zixin Pharmaceutical made in order to win this honor?

 

Chinese medicine master country

In today's world, whoever masters the right to formulate standards, has mastered the initiative of technology and economic competition to a certain extent. With the huge medical value and market potential of traditional medicine, Chinese medicine has rapidly spread in more and more countries and regions, and the international voice and demand for TCM standardization are increasing.

Li Daning, honorary director of the Chinese Medicine Association's Chinese Medicine Testing and Certification Technology Committee, believes that the development of Chinese medicine standards to the international arena through the operation of the International Organization for Standardization (ISO) is a landmark event in the history of Chinese medicine development.

It is understood that the International Organization for Standardization, as the world's largest international standards-setting body, has exerted tremendous influence on the economy, trade, exchanges and cooperation in the world. In 2009, with the wide spread and application of Chinese medicine in the world, the demand for international standards of Chinese medicine has become increasingly prominent. Under the joint efforts of the National Standardization Administration and the State Administration of Traditional Chinese Medicine, the International Organization for Standardization has established the standardization of traditional Chinese medicine. Committee, code TC249. So far, the world's largest and most authoritative international standardization organization has an international standard development platform tailored for Chinese medicine.

Li Daning told reporters that the establishment of ISO/TC249 aims to establish a new pattern of Chinese medicine standardization through standardized channels, promote the healthy development of traditional medicine represented by Chinese medicine in the world, and realize the vision of Chinese medicine to serve the health of the world people. .

It is reported that the secretary country of ISO/TC249 is China, and an international conference attended by all members (a total of 34 members) will be held from late May to early June each year.

According to the data, in 2015, when the sixth plenary meeting of ISO/TC249 was held in Beijing, the official name of Chinese was “International Organization for Standardization/Traditional Chinese Medicine (Tentative Name) Technical Committee”. The closing ceremony uploaded a message and cancelled the provisional name. "Three words.

"The closing ceremony decided to cancel the 'tentative name'. On the surface, there are only three words missing, but the gold content is very high, and the future will show great historical value." Guo Chunsheng, chief consultant of Zixin Pharmaceutical, believes that this official naming, Let more people in the world share Chinese medicine resources, which has a milestone significance in promoting the standardization of Chinese medicine and accelerating the internationalization of Chinese medicine. From a certain perspective, this formal naming is to confirm the status of the Chinese traditional Chinese medicine country and lay a solid foundation for the globalization of the Chinese medicine industry.

“Ginseng is the largest variety of traditional Chinese medicine. China’s overall level in terms of planting area, export volume, and scientific research strength is the highest in the world.” Li Daning, honorary director of the Chinese Medicine Association’s Chinese Medicine Testing and Certification Technology Committee, believes that the International Organization for Standardization The formulation of international standards for ginseng will greatly promote the globalization of China's ginseng industry.

317 resolutions

Time back to two years ago.

A heavy news was uploaded at the 6th plenary meeting of ISO/TC249. The contents of the 203 resolutions are: ISO/TC249 of the International Organization for Standardization, to the National Standardization Administration, the State Administration of Traditional Chinese Medicine, and all volunteers. And Zixin Pharmaceutical and other units expressed their sincere gratitude for the contribution made to the success of this meeting.

“Thank you for your contribution to the company in the form of resolutions, and for the first time at the international conference!” An industry authority believes that 203 resolutions have enabled Zixin Pharmaceutical to gain international recognition and its image is deeply rooted in the hearts of member states. The development of standards laid the foundation.

The reporter was informed at the eighth plenary meeting of ISO/TC249 that following the sixth plenary meeting of ISO/TC249 held in Beijing in 2015, Zixin Pharmaceutical once again became the sole authorized support unit of the conference, and the 317 resolutions of the conference were again against Xin Pharmaceutical expressed its gratitude.

What kind of contribution has Zixin Pharmaceutical made in order to win such a privilege?

Guo Chunsheng, the chief consultant of Zixin Pharmaceutical Co., gave the standard answer: Zixin Pharmaceutical has become the only authorized support unit of the conference as a domestic excellent pharmaceutical company. Zixin Pharmaceutical has been committed to promoting the international standards of ginseng and the development of international standards for Chinese medicine. .

In this regard, Li Daning, honorary director of the Chinese Medicine Association of Chinese Medicine Testing and Certification Technology Committee, also deeply agrees that Jilin Province is the main ginseng producing area in China and the world, and Zixin Pharmaceutical has made outstanding contributions in the deep cultivation, processing and sales of ginseng. It has effectively promoted the development of ISO/TC249 international standards for ginseng and international standards for Chinese medicine, and also provided demonstrations for the development of international standards for other Chinese medicinal herbs.

It is understood that Zixin Pharmaceutical is located in Liuhe County, Tonghua City, a famous medicine city in Jilin Province. It was established in May 1998. It is a pillar of the three major industries of Chinese patent medicine, ginseng industry and gene sequencer, integrating scientific research and production. A high-tech joint-stock enterprise that sells, grows medicinal plants and animals. The company was listed on the Shenzhen Stock Exchange in March 2007 and has grown into a large domestic pharmaceutical listed group with more than 10 molecular companies, more than 2,000 employees and a total market value of nearly 10 billion yuan.

Urgent task

Lu Aiping, Dean of the School of Chinese Medicine of Hong Kong Baptist University, has long been engaged in the classification of disease syndrome and the international standardization of Chinese medicine. Since the establishment of ISO/TC249 in 2009, he has been the head of the Chinese delegation of the organization and actively participated in the formulation of Chinese medicine trade. International standards for Chinese herbal medicines, Chinese medicine products, acupuncture equipment, and Chinese medicine diagnosis and treatment equipment.

"Ginseng is first of all Chinese, then international. The efficacy and cultural heritage of Chinese ginseng is well known." Lu Aiping believes that the urgent task of China's ginseng industry development is to set international standards, and hope that Zixin Pharmaceutical can organize a stronger team. Support this work.

Why do many experts and scholars have high hopes for Zixin Pharmaceutical?

"The development of a standard is crucial to the development of the industry." Guo Chunsheng, the chief consultant of Zixin Pharmaceutical, told the reporter that Zixin Pharmaceutical is a company mainly engaged in the production and processing of traditional Chinese medicine. Through academic and medical research, Enterprises have taken the international leading position in formulating international standards for Chinese medicine and ginseng.

When South Korea proposed the standard of red ginseng, Zixin Pharmaceutical realized that it could no longer "silence" and actively invested in the standardization of ginseng. To win a stronger international discourse power for China and to help the development of the national industry, it has become the persistence and belief of Zixin Pharmaceutical's standardization work.

It is understood that Zixin Pharmaceutical actively participates in the formulation of ginseng standardization at different levels, such as international, national, industry and local, and participates in the formulation of 4 local standards for ginseng food in Jilin Province, 38 enterprise standards, and 4 ginseng health food enterprise standards. In 2012, Zixin Pharmaceutical participated in the third plenary meeting of ISO/TC249 and actively participated in the international standard setting work of the International Organization for Standardization, "Chinese Medicine - Ginseng Seed Seedlings - Part 1: Asian Ginseng". It was released by the International Organization for Standardization in the first half of 2014 and became one of the first international standards for Chinese medicine published by the International Organization for Standardization. In May 2014, Zixin Pharmaceutical participated in the fifth plenary meeting of ISO/TC249 and actively participated in the formulation of the requirements of the production process of red ginseng industry.

"We call on more domestic enterprises to actively participate in the formulation of international standards for ginseng, so as to grasp the initiative of international standards development, provide opportunities for enterprise development, and enable Chinese medicine and ginseng industry to go global." Guo Chunsheng, chief consultant of Zixin Pharmaceutical Co., Ltd. This hope.